Hosted on MSN47m
Keros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A ReboundKeros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...
Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...
A systematic review of quality-of-life tools available specifically for pulmonary arterial hypertension (PAH) reveals that ...
The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...
Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.
Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure ...
The Tropos trial is designed to test three doses of Keros’ cibotercept in patients with pulmonary arterial hypertension who ...
Merck’s new pulmonary arterial hypertension (PAH) medication has posted another batch of promising clinical trial data, ...
Keros Therapeutics said on Thursday that it has voluntarily halted usage of its 3.0 milligram (mg) and 4.5 mg doses of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback